Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen

O. Klein, S. Linn, C. Davidson, A. Hadary, A. Shukha, J. Zidan, A. Eitan, A. I. Kook

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Early detection is crucial for successful treatment of all types of cancer. The specificity and sensitivity of the current methods vary from 50% to 80%. The use of specific tumor antigens and cytometric technology has resulted in the development of a new procedure for the early detection of breast tumors. This new method is reported. The test utilizes static cytometry, which records polarization and intensity changes in fluorescent light emitted from each individual lymphocyte obtained from tumor-bearing patients stimulated by the relevant specific tumor antigen. Using MUC-1/SEC as the specific antigen, we detected breast tumors with 85% specificity and 81% sensitivity in 137 breast tumor-bearing women. A significant linear correlation was found between the SCM test and the conventional classification of relative risk for breast cancer in benign lesions, suggesting that this is a precise method that could be used in mass screening for early detection of breast cancer.

Original languageEnglish
Pages (from-to)478-483
Number of pages6
JournalBreast
Volume11
Issue number6
DOIs
StatePublished - Dec 2002
Externally publishedYes

Bibliographical note

Funding Information:
*The work was supported by the Israel Association for the Fight Against Cancer #9600210 and #9720282. Address correspondence to: Dr A. I. Kook, Research Department, Sieff Government Hospit al, Safed 13100, Israel. Tel.: +972 6 682 8091; Fax: + 972 6 692 3753; E-mail: kookai@zahav.net.il Received: 24 July 2002 Revised: 13 August 2002 Accepted: 28 August 2002

Fingerprint

Dive into the research topics of 'Early detection of malignant process in benign lesions of breast tumor by measurements of changes in structuredness of cytoplasmic matrix in circulating lymphocytes (SCM test) reinduced in vitro by specific tumor antigen'. Together they form a unique fingerprint.

Cite this